INTEGRATIVE ONCOLOGY:
MODERN TREATMENT + SUPPORTIVE CARE

Integrative oncology is a patient-centred, evidence-informed field that combines conventional cancer treatment with rigorously evaluated complementary therapies to optimise quality of life and clinical outcomes. The defining word is "integrative" — complementary therapies are used alongside standard treatment, never instead of it.

“Integrative oncology is explicitly not alternative medicine. Patients who reject proven treatment in favour of unproven alternatives risk their lives. Complementary therapies earn their place by improving wellbeing within, not as a replacement for, evidence-based oncology.”

• Integrative Oncology IS:

  Evidence-based complementary therapies (acupuncture, exercise, MBSR, yoga, nutrition counselling, TCM) used alongside chemotherapy, radiotherapy, surgery, and targeted therapy to manage side effects and improve quality of life. All practices are evaluated against clinical evidence before recommendation.

• Integrative Oncology IS NOT:

  Alternative medicine — using unproven therapies instead of conventional treatment. Rejecting chemotherapy for curable lymphoma in favour of herbs, or delaying surgery for early breast cancer to pursue detox diets, is not integrative oncology. It is a dangerous path that costs lives that standard treatment would have saved.

• Mind-Body Practices

  Mindfulness-based stress reduction (MBSR), cognitive behavioural therapy (CBT), yoga, guided imagery, hypnosis, and relaxation techniques — addressing psychological, emotional, and cognitive dimensions of the cancer experience with the strongest RCT evidence base in integrative oncology.

• Physical and Traditional Medicine Modalities

  Acupuncture, exercise oncology, massage therapy, nutrition counselling, Traditional Chinese Medicine (TCM), Ayurveda, herbal medicine, and music therapy — each with varying levels of evidence and specific indications within the cancer care pathway.

The Society for Integrative Oncology (SIO) and ASCO published updated clinical practice guidelines in 2022–2023 — the most authoritative evidence synthesis for integrative oncology. Evidence grades directly inform clinical recommendations.

Cancer-related fatigue (CRF) affects 70–100% of patients during active treatment and persists in 20–30% of survivors. Unlike normal tiredness, it is not relieved by rest. Exercise is now the most evidence-supported intervention — a paradigm shift from the old advice to "rest during treatment".

• Exercise: The Most Evidence-Supported CRF Intervention

  Cochrane review (100+ RCTs): aerobic exercise and resistance training significantly reduce CRF both during active treatment and survivorship — with a larger effect size than any pharmacological agent. The CARE Phase III RCT showed supervised exercise during breast cancer chemotherapy reduced fatigue, improved fitness, and was safe with no increase in adverse events.

• Mindfulness-Based Stress Reduction (MBSR)

  An 8-week structured programme of mindfulness meditation, body scan, and gentle yoga. Multiple RCTs in breast cancer, lymphoma, and mixed cancer populations demonstrate significant improvements in fatigue, sleep, anxiety, and quality of life. CBT for insomnia (CBT-I) is the most effective treatment for cancer-related sleep disturbance — Grade A recommendation.

• Acupuncture for CRF

  A systematic review in the Journal of Clinical Oncology (Molassiotis et al.) across 7 RCTs found statistically significant CRF improvements vs sham acupuncture. Chinese oncology guidelines specifically recommend acupuncture for fatigue as an adjunct to standard supportive care. Available at China's tier-one cancer centres as part of the integrated TCM programme.

The following table maps the most clinically significant cancer treatment side effects to the best-evidenced integrative interventions — enabling patients to identify which complementary therapies are specifically supported for their symptoms.

Surveys show 60–80% of cancer patients worldwide use supplements or traditional preparations during treatment — and the majority do not disclose this to their oncologist. Some supplements have clinical benefit; others are dangerous. The distinction is critical.

Exercise is medicine in oncology. The paradigm has shifted completely — from "rest during treatment" to structured exercise prescription as standard supportive care. The key is individual prescription: type, intensity, frequency, and progression matched to the patient's treatment phase and fitness.

1. 1

   Pre-Exercise Safety Assessment

   Check for contraindications before starting: severe anaemia (Hb <8 g/dL — rest), febrile neutropenia (stop until resolved), recent surgery (wait for wound healing), unstable bone metastases (fracture risk assessment required). Avoid swimming and public gym equipment during neutropenia.

2. 2

   Start Low, Build Slowly (Sedentary Patients)

   For previously sedentary patients: begin with 10–15 minutes of walking three times per week. Increase duration by 5 minutes every 1–2 weeks as tolerated. Even modest activity is significantly better than none. Focus on consistency over intensity in the early weeks.

3. 3

   Aerobic Exercise Target (Active Treatment)

   Target during active treatment: 90–120 minutes per week of moderate-intensity aerobic activity (walking, cycling, swimming). Rate of perceived exertion 4–6/10. Can be split into multiple shorter sessions. Reduces fatigue, improves mood, preserves cardiovascular fitness, and supports treatment tolerance.

4. 4

   Resistance Training (2–3×/Week)

   Two to three resistance sessions per week using bodyweight, resistance bands, or light weights. Preserves lean muscle mass during treatment, counters cancer cachexia, and is the most important intervention for ADT-related muscle and bone loss in prostate cancer patients. Start with one set of 10–15 reps per exercise.

5. 5

   Survivorship Target

   150 minutes per week of moderate-intensity aerobic activity — equivalent to WHO general population recommendation. Physically active colorectal cancer survivors have 20–30% lower cancer-specific mortality. For breast cancer: exercise is associated with reduced recurrence risk in multiple large cohort studies.

China and India are uniquely positioned among countries providing cancer care to international patients: their traditional medicine systems (TCM and Ayurveda) are not "alternative" but formally integrated into national oncology practice, with clinical evidence and safety frameworks that distinguish them from unregulated folk medicine.

• TCM in Chinese Oncology: Formal Integration

  China's national health policy formally integrates TCM with Western medicine. At tier-one cancer centres (Fudan Shanghai Cancer Centre, CAMS Beijing), TCM departments operate alongside chemotherapy and radiation units. Chinese clinical guidelines recommend: acupuncture for CINV, pain, CIPN, fatigue, xerostomia; Astragalus (Huang Qi) formulations for myelosuppression and fatigue; Qi Gong for fatigue and immune function.

• Yoga in Cancer: The RCT Evidence Base

  Yoga has been evaluated in >50 RCTs in cancer patients — more than any other traditional Indian practice. A Cochrane systematic review found significant improvements in fatigue, sleep quality, anxiety, and depression in cancer patients. Yoga is a Grade B SIO-ASCO recommendation. India's SVYASA (yoga university) and Tata Memorial Centre offer cancer-adapted yoga programmes for treatment and survivorship.

• Ayurvedic Preparations with Clinical Evidence

  Ashwagandha: multiple RCTs show improved fatigue, QoL, and weight in chemotherapy patients. Turmeric/curcumin: evidence for oral mucositis reduction and anti-inflammatory properties (bioavailability limits clinical translation). Triphala mouthwash: RCT evidence for reducing radiation-induced oral mucositis in H&N cancer. All require oncologist disclosure before use.

• Panchakarma: Avoid During Active Treatment

  Panchakarma — Ayurveda's intensive cleansing programme (therapeutic vomiting, purgation, enemas) — is absolutely contraindicated during active cancer treatment. Intensive purging during chemotherapy risks dangerous electrolyte disturbances, dehydration, and dangerous interactions with toxic chemotherapy agents. Panchakarma should only be considered during established survivorship, under medical supervision.

Nutrition during cancer treatment is surrounded by competing claims and myths. The evidence-based integrative oncology approach focuses on a few high-impact, proven principles — and firmly rejects dangerous myths like "starving the cancer" through extreme restriction.

1. 1

   Priority 1: Eat Enough — Caloric Adequacy Above All

   The primary goal is to eat enough to maintain weight. Patients who restrict food in the belief that "starving the cancer" helps are actually starving themselves — impairing treatment tolerance, causing muscle loss, and reducing immunity. Clinical evidence does not support therapeutic caloric restriction during active treatment.

2. 2

   Priority 2: Adequate Protein Intake

   ESPEN guidelines recommend 1.2–1.5g protein per kg body weight per day for cancer patients — significantly higher than the 0.8g/kg for healthy adults. Protein preserves lean muscle, supports immune function, and maintains treatment tolerance. Sources: eggs, lean meat, fish, legumes, dairy, tofu, nuts.

3. 3

   Priority 3: Predominantly Plant-Based Dietary Pattern

   Post-diagnosis dietary patterns high in fruits, vegetables, whole grains, and legumes with moderate lean protein are associated with improved survival outcomes in breast, colorectal, and prostate cancer survivors in large observational studies. This does not mean exclusion of animal protein — it means plant foods should predominate.

4. 4

   Priority 4: Omega-3 Supplementation (EPA/DHA)

   Multiple RCTs and meta-analyses support EPA/DHA supplementation (1.5–2.4g EPA daily) for preserving muscle mass, reducing cancer cachexia, improving appetite, and anti-inflammatory effects during chemotherapy — particularly for GI and lung cancers. Fish oil at these doses has good safety data.

5. 5

   What to Avoid: Nutritional Red Flags

   Avoid: extreme caloric restriction / fasting diets (no RCT evidence for benefit, significant harm risk); high-dose antioxidants during chemotherapy; grapefruit and Seville orange with targeted therapy (CYP3A4 inhibition); unreviewed herbal weight-loss teas. Moderate alcohol reduction is evidence-supported for breast cancer survivors.

Completing treatment does not mean returning to normal. Many survivors experience persistent fatigue, neuropathy, cognitive effects ("chemo brain"), and fear of recurrence for months or years. Integrative oncology provides evidence-based tools for each of these survivorship challenges.

• Fear of Recurrence: CBT-Based Therapy

  Fear of cancer recurrence (FCR) affects 50–70% of survivors and is the most prevalent survivorship concern. Cognitive behavioural therapy targeting FCR — including the CanThrive and ConquerFear RCTs — demonstrates significant reductions in FCR severity. Referral to a psycho-oncologist trained in CBT for FCR is the recommended intervention for clinically significant FCR.

• Cognitive Effects ("Chemo Brain")

  Cognitive impairment — difficulties with memory, concentration, and executive function — affects 20–30% of chemotherapy recipients and can persist for years. Evidence-based interventions: cognitive rehabilitation programmes, MBSR, aerobic exercise (shown to improve cognitive function), and sleep optimisation. Referral to neuropsychology if significant functional impairment.

• Exercise in Survivorship: Recurrence Risk Reduction

  Physically active colorectal cancer survivors have 20–30% lower cancer-specific mortality. Post-diagnosis exercise is associated with improved survival in breast, prostate, and endometrial cancer survivorship. 150 min/week of moderate aerobic activity is the WHO-aligned target. Resistance training 2–3×/week preserves muscle, bone density, and metabolic health.

• Persistent Fatigue and Neuropathy

  Persistent CRF in survivorship: exercise first (Grade A), then MBSR, acupuncture. For persistent CIPN: acupuncture has the best evidence (3 RCTs positive), alongside duloxetine (pharmacological). For sleep disturbance: CBT-I is the gold standard — superior to sleep medications for long-term outcomes. Both available through CancerFax partner centre programmes.

Data from systematic reviews, meta-analyses, and landmark RCTs defining the clinical impact of integrative interventions.

• 100+RCTs Supporting Exercise for Cancer FatigueCochrane review: exercise is the most evidence-supported CRF intervention — superior to all pharmacological options for most patients.
• 50–70%Survivors with Fear of RecurrenceThe most prevalent survivorship concern — moderate FCR is normal, but clinically significant FCR requires CBT-based psycho-oncology referral.
• 60–80%Cancer Patients Using SupplementsGlobal surveys: the majority do not disclose this to their oncologist — creating significant unrecognised drug-herb interaction risk.
• 40–70%Chemotherapy Level Reduction by St John's WortSt John's Wort reduces irinotecan, imatinib, erlotinib, and docetaxel drug levels by 40–70% — an absolute contraindication during cancer treatment.

China and India are uniquely positioned for integrative oncology — their traditional medicine systems are formally integrated into national oncology practice, not offered as parallel alternatives. CancerFax coordinates access to these services for international patients.

Frequently Asked Questions